Astria Therapeutics, Inc.
ATXS
$4.04
$0.061.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.61% | 5.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.99% | 0.73% | |||
| Operating Income | -1.99% | -0.73% | |||
| Income Before Tax | -4.45% | -1.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.45% | -1.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.45% | -1.50% | |||
| EBIT | -1.99% | -0.73% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.10% | 0.84% | |||
| Normalized Basic EPS | -4.11% | 0.86% | |||
| EPS Diluted | -4.10% | 0.84% | |||
| Normalized Diluted EPS | -4.11% | 0.86% | |||
| Average Basic Shares Outstanding | 0.34% | 2.36% | |||
| Average Diluted Shares Outstanding | 0.34% | 2.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||